Optimal treatment of metastatic pancreatic cancer

Gut

Volumn 59, Issue 11, 2010, Pages 1454-1455

  Cunningham, David ^a   Chong, Irene ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CISPLATIN; CONATUMUMAB; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MK 0646; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; GENE MUTATION; HUMAN; METASTASIS; NOTE; ONCOGENE K RAS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADENOCARCINOMA; PANCREAS TUMOR;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; PANCREATIC NEOPLASMS;

EID: 78049512083     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.220954     Document Type: Note

References (15)

1. Jemal A, Siegal R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. Published Online First: 2010 Jul 7 doi:10.3322/caac.20073.
2. Burris HA3rd, Moore MJ, Anderson J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomised trial. J Clin Oncol 1997;15:2403-13.
3. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6.
4. Cunningham D, Chau I, Stocken DD, et al. Phase III randomised comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009;27:5513-18.
5. Conroy T, Desseigne F, Ychou M, et al. Randomised phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. J Clin Oncol 2010;28:15s (Suppl; abstr 4010).
6. Pelzer U, Kubica K, Stieler J, et al. A randomised trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 2008;26 (May 20 Suppl; abstr 4508).
7. Buchholz M, Gress TM. Molecular changes in pancreatic cancer. Expert Rev Anticancer Ther 2009;9:1487-97.
8. Javle MM, Varadhachary GR, Shroff RT, et al. Phase I/II study of MK-0646, the humanised monoclonal IGF-1R antibody in combination with gemcitabine or gemcitabine plus erlotinib for advanced pancreatic cancer. J Clin Oncol 2010;28:15s (Suppl; abstr 4039).
9. Kindler HL, Richards DA, Stephenson J, et al. A placebo-controlled, randomised phase II study of conatumumab (C) or AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients with metastatic pancreatic cancer (mPC). J Clin Oncol 2010;28:15s (Suppl; abstr 4035).
10. Rai P, Mai Z, Chang S, et al. Targeting intracellular VEGF using nanotechnology for subcellular delivery of bevacizumab improves efficacy of combination therapy against pancreatic cancer. Mol Cancer Ther 2009;8:12 (Suppl 1; abstr A2).
11. Zheng LZ, Rai P, Spring B, et al. Combination therapy targeting EGFR/MET crosstalk using nanotechnology improves photodynamic therapy treatment of pancreatic cancer. Mol Cancer Ther 2009;8: 12 (Suppl 1; abstr A127).
12. Maitra A, Rajeshkumar NV, Rudek M, et al. Nab-paclitaxel targets tumour stroma and results, combined with gemcitabine, in high efficacy against pancreatic cancer. Mol Cancer Ther 2009;8: 12 (Suppl 1; abstr C246).
13. Von Hoff DD, Ramanathan R, Borad M, et al. SPARC correlation with response to gemcitabine plus nab-paclitaxel in patients with advanced metastatic pancreatic cancer: A phase I/II study. J Clin Oncol 2009;27:15s (Suppl; abstr 4525).
14. Starling N, Hawkes EA, Chau I, et al. A dose-escalation study of gemcitabine (Gem) plus oxaliplatin (Ox) in combination with imatinib in patients with gemcitabine-refractory advanced pancreatic adenocarcinoma. J Clin Oncol 2010;28:15s(Suppl; abstr 4155).
15. Dahan L, Bonnetain F, Ychou M, et al, for the Fédération Francophone de Cancérologie Digestive (FFCF). Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). Gut 2010;59:1527-34.